Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−29.58 M USD
10.04 M USD
142.01 M
About Mereo BioPharma Group plc
Sector
Industry
CEO
Denise Vera Scots-Knight
Website
Headquarters
London
Founded
2015
FIGI
BBG0113HY1Y8
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.